Satri-cel represents a major milestone in cancer treatment as the first CAR T cell therapy approved for a solid tumor. For Larry Black, this advance in cell therapy became the reason to travel from the United States to China.
A novel nanobody-based CAR-T therapy targeting Claudin18.2 has demonstrated remarkable efficacy and safety in gastric and gastroesophageal junction cancers, achieving a 66.7% response rate and sustained complete remission beyond 60 weeks in early clinical trials.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.